The Cambridge, Mass.-based drugmaker did not specify a projected timeline for when the new flu vaccine could be on the market, while Moderna CEO Stéphane Bancel said earlier this summer that he expects its candidate to be commercially available “over the next two to three years.”
In late August, Moderna filed suit against Pfizer for its use of mRNA technology, which paints an uneasy backdrop as they work to prove efficacy in other mRNA vaccines.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
